Incidence of mortality · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
MDAC + hospital intervention showed no clear difference in incidence of mortality compared with hospital intervention (low certainty).
1 finding from 1 review
Incidence of adverse events · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
MDAC + hospital intervention showed no clear difference in incidence of adverse events compared with hospital intervention (low certainty).
1 finding from 1 review
Incidence and severity of symptoms of poisoning: incidence of need for intubation · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
MDAC + hospital intervention showed no clear difference in incidence and severity of symptoms of poisoning: incidence of need… compared with hospital intervention (low certainty).
1 finding from 1 review
Duration of intubation · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Low
Drug absorption: cardenolide: AUC (µg/L × h) · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
1 finding from 1 review
Hospitalization · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of admissions to the ICU · first aid in patients with acute oral poisoning (benzodiazepines, yellow oleander or combinations of different drugs)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence
It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to progression
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
1 finding from 1 review
Disease‐specific survival
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence
Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).
1 finding from 1 review
Time to progression
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
1 finding from 1 review
Disease‐specific survival
1 finding from 1 review
Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with single‐dose, postoperative MMC‐PD (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review